Clene Inc. (CLNN)
- Previous Close
0.3865 - Open
0.3917 - Bid 0.3859 x 200
- Ask 0.3939 x 300
- Day's Range
0.3610 - 0.3998 - 52 Week Range
0.2500 - 1.0900 - Volume
438,800 - Avg. Volume
914,996 - Market Cap (intraday)
50.192M - Beta (5Y Monthly) 0.49
- PE Ratio (TTM)
-- - EPS (TTM)
-0.4700 - Earnings Date Aug 12, 2024 - Aug 16, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
5.00
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company also develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, it markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.
clene.comRecent News: CLNN
Performance Overview: CLNN
Trailing total returns as of 5/13/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CLNN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CLNN
Valuation Measures
Market Cap
49.64M
Enterprise Value
46.80M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
62.02
Price/Book (mrq)
3.71
Enterprise Value/Revenue
74.66
Enterprise Value/EBITDA
-1.13
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-52.33%
Return on Equity (ttm)
-595.47%
Revenue (ttm)
654k
Net Income Avi to Common (ttm)
-49.5M
Diluted EPS (ttm)
-0.4700
Balance Sheet and Cash Flow
Total Cash (mrq)
35M
Total Debt/Equity (mrq)
240.19%
Levered Free Cash Flow (ttm)
-16.17M
Research Analysis: CLNN
Company Insights: CLNN
CLNN does not have Company Insights